{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:20:14Z","timestamp":1791811214146,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104956","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:13:02Z","timestamp":1786201982000},"page":"104956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center \u201cSurgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)\u201d"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-506X","authenticated-orcid":false,"given":"Andreas","family":"du Bois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-5601","authenticated-orcid":false,"given":"Giovanni","family":"Aletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Langstraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Traut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-5005","authenticated-orcid":false,"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-4059","authenticated-orcid":false,"given":"Francesco","family":"Multinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-8666","authenticated-orcid":false,"given":"Luigi","family":"de Vitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-3015","authenticated-orcid":false,"given":"Irina","family":"Tsibulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7590","authenticated-orcid":false,"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Garbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simi","family":"Warring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4038-7544","authenticated-orcid":false,"given":"Nicholas","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-8913","authenticated-orcid":false,"given":"Dennis","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijgc.2026.104956_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104956_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104956_bib3","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104956_bib4","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104956_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104956_bib6","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1245\/s10434-019-07516-3","article-title":"Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome","volume":"26","author":"Hall","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib7","doi-asserted-by":"crossref","first-page":"170.e1","DOI":"10.1016\/j.ajog.2019.07.050","article-title":"Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?","volume":"222","author":"Klein","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104956_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104956_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104956_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.109996","article-title":"Incidence and survival of rare female genital tract cancers in Europe: the EUROCARE-6 study","volume":"51","author":"Gatta","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104956_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2017.04.007","article-title":"Reporting \u2018Denominator\u2019 data is essential for benchmarking and quality standards in ovarian cancer","volume":"146","author":"Phillips","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104956_bib12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104956_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104956_bib14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104956_bib15","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","article-title":"European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery","volume":"26","author":"Querleu","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/ijgc-00009577-200503000-00001","article-title":"Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer","volume":"15","author":"Du Bois","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104956_bib17","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104956_bib18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104956_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102756","article-title":"Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis","volume":"36","author":"Kim","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104429","article-title":"RECOVER (recurrence ovarian cancer real life): a MITO (multicenter Italian trials in ovarian cancer) real-world study comparing cytoreductive surgery and chemotherapy in platinum-sensitive recurrent ovarian cancer with known BRCA status","volume":"36","author":"Rosati","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","article-title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial","volume":"36","author":"Harter","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104956_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2024.03.006","article-title":"Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer","volume":"186","author":"Ehmann","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104956_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1245\/s10434-022-12681-z","volume":"30","author":"Glajzer","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104956_bib26","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104956_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.101604","article-title":"Prospective multicentre evaluation of secondary cytoreductive surgery in the era of PARP-inhibitors (CONCEPT) in relapsed epithelial ovarian cancer","volume":"35","author":"Fotopoulou","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:36:04Z","timestamp":1788348964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S1048891X26004871"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104956","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center \u201cSurgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)\u201d","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104956"}}